These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 31803473

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials.
    Hanania NA, Korenblat P, Chapman KR, Bateman ED, Kopecky P, Paggiaro P, Yokoyama A, Olsson J, Gray S, Holweg CT, Eisner M, Asare C, Fischer SK, Peng K, Putnam WS, Matthews JG.
    Lancet Respir Med; 2016 Oct; 4(10):781-796. PubMed ID: 27616196
    [Abstract] [Full Text] [Related]

  • 3. Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids.
    Noonan M, Korenblat P, Mosesova S, Scheerens H, Arron JR, Zheng Y, Putnam WS, Parsey MV, Bohen SP, Matthews JG.
    J Allergy Clin Immunol; 2013 Sep; 132(3):567-574.e12. PubMed ID: 23726041
    [Abstract] [Full Text] [Related]

  • 4. Seasonal variability of exacerbations of severe, uncontrolled eosinophilic asthma and clinical benefits of benralizumab.
    DuBuske L, Newbold P, Wu Y, Trudo F.
    Allergy Asthma Proc; 2018 Sep 04; 39(5):345-349. PubMed ID: 30077185
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of lebrikizumab in adult patients with mild-to-moderate asthma not receiving inhaled corticosteroids.
    Korenblat P, Kerwin E, Leshchenko I, Yen K, Holweg CTJ, Anzures-Cabrera J, Martin C, Putnam WS, Governale L, Olsson J, Matthews JG.
    Respir Med; 2018 Jan 04; 134():143-149. PubMed ID: 29413502
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Ferguson GT, FitzGerald JM, Bleecker ER, Laviolette M, Bernstein D, LaForce C, Mansfield L, Barker P, Wu Y, Jison M, Goldman M, BISE Study Investigators.
    Lancet Respir Med; 2017 Jul 04; 5(7):568-576. PubMed ID: 28545978
    [Abstract] [Full Text] [Related]

  • 9. Heightened response of eosinophilic asthmatic patients to the CRTH2 antagonist OC000459.
    Pettipher R, Hunter MG, Perkins CM, Collins LP, Lewis T, Baillet M, Steiner J, Bell J, Payton MA.
    Allergy; 2014 Sep 04; 69(9):1223-32. PubMed ID: 24866478
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma: Effects Across a Broad Range of Eosinophil Counts.
    Corren J, Weinstein S, Janka L, Zangrilli J, Garin M.
    Chest; 2016 Oct 04; 150(4):799-810. PubMed ID: 27018175
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and tolerability of salmeterol/fluticasone propionate versus montelukast in childhood asthma: A prospective, randomized, double-blind, double-dummy, parallel-group study.
    Maspero J, Guerra F, Cuevas F, Gutierrez JP, Soto-Ramos M, Anderton S, Mechali D, Chan R, Pedersen S.
    Clin Ther; 2008 Aug 04; 30(8):1492-504. PubMed ID: 18803991
    [Abstract] [Full Text] [Related]

  • 15. A 12-week, multicenter, randomized, partially blinded, active-controlled, parallel-group study of budesonide inhalation suspension in adolescents and adults with moderate to severe persistent asthma previously receiving inhaled corticosteroids with a metered-dose or dry powder inhaler.
    Murphy K, Noonan M, Silkoff PE, Uryniak T.
    Clin Ther; 2007 Jun 04; 29(6):1013-26. PubMed ID: 17692718
    [Abstract] [Full Text] [Related]

  • 16. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies.
    Hanania NA, Noonan M, Corren J, Korenblat P, Zheng Y, Fischer SK, Cheu M, Putnam WS, Murray E, Scheerens H, Holweg CT, Maciuca R, Gray S, Doyle R, McClintock D, Olsson J, Matthews JG, Yen K.
    Thorax; 2015 Aug 04; 70(8):748-56. PubMed ID: 26001563
    [Abstract] [Full Text] [Related]

  • 17. Adding omalizumab to the therapy of adolescents with persistent uncontrolled moderate--severe allergic asthma.
    Massanari M, Milgrom H, Pollard S, Maykut RJ, Kianifard F, Fowler-Taylor A, Geba GP, Zeldin RK.
    Clin Pediatr (Phila); 2009 Oct 04; 48(8):859-65. PubMed ID: 19564449
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.